EUCTR2009-018267-27-ES进行中（未招募）不适用
A 5-Year, Extension, Follow-up, Blinded-Outcomes Trial of Subjects Having Received Stannsoporfin or Placebo in Clinical Trial 64,185-202Un estudio ciego de seguimiento y ampliación de 5 años de duración de pacientes que recibieron estansoporfina o placebo en el ensayo clínico 64.185-202
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Sujetos que hayan recibido el PEI en el ensayo clínico 64.185-202
- •- Consentimiento informado escrito
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Clinical observation study of 5-year survivals in patients with newly diagnosed acute myelogenous leukemia (AML), myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML) in Japan Adult Leukemia Study GroupAcute myelogenous leukemia (AML), myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML)JPRN-UMIN000008371Japan Adult Leukemia Study Group6,100
已完成
不适用
Clinical observation study of 5-year survivals in patients with newly diagnosed acute lymphoblastic leukemia (ALL) in Japan Adult Leukemia Study Group (JALSG). (JALSG-ALL-CS-12)Acute lymphoblastic leukemiaJPRN-UMIN000007653Japan Agency for Medical Research and Development Japan Adult Leukemia Study Group733
进行中（未招募）
1 期
AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Subjects With Mild Cognitive Impairment Due to Alzheimer DiseaseEUCTR2013-004984-30-GBTakeda Development Centre Europe Ltd40
招募中
2 期
To study efficacy, safety and tolerability of intra-artecular regimens of LNA043 versus placebo in adult patients with symptomatic knee osteoarthritisCTRI/2021/10/037098ovartis Healthcare Pvt Ltd
进行中（未招募）
1 期
A study aiming to collect data and provide a better understanding of the long-term outcome of imlifidase in treatment of immunological graft rejection in kidney transplant patientsAntibody-mediated rejection in kidney transplant patientsMedDRA version: 20.0Level: PTClassification code 10023439Term: Kidney transplant rejectionSystem Organ Class: 10021428 - Immune system disordersEUCTR2020-004777-49-ATHansa Biopharma30